Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology released interim results from its Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 mutated, metastatic NSCLC.

Click to view original post